---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-037815"
form_type: "8-K"
ticker: "ERNA"
cik: "0000748592"
company_name: "Ernexa Therapeutics Inc."
filed_at: "2024-09-23T23:59:59+00:00"
generated_at: "2026-05-31T02:37:29.535641+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Eterna Therapeutics receives Nasdaq delisting notice for failure to regain compliance with equity rule

## Summary
- On Sept 17, 2024, Nasdaq determined Eterna did not meet the extension terms to demonstrate compliance with the Minimum Stockholders' Equity Rule (stockholders' equity < $2.5M as of Dec 31, 2023).
- Trading of ERNA common stock will be suspended on Sept 26, 2024 unless a hearing request is filed by Sept 24, 2024.
- Company intends to timely request a hearing with Nasdaq's Hearings Panel to appeal the determination; a stay will be in effect pending decision.
- Hearings typically scheduled 30-45 days after request; panel decision within 30 days of hearing; no assurance of success.
- If appeal fails or no request, a Form 25-NSE will be filed, removing ERNA from Nasdaq listing and registration.

## SEC filing metadata
- accession: 0001493152-24-037815
- form_type: 8-K
- ticker: ERNA
- cik: 0000748592
- company_name: Ernexa Therapeutics Inc.
- filed_at: 2024-09-23T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/748592/000149315224037815/0001493152-24-037815-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/748592/000149315224037815/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-037815
- JSON: https://secwatch.observer/filing/0001493152-24-037815.json
- Plain text: https://secwatch.observer/filing/0001493152-24-037815.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.